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of colon-targeted formulations, but little information is available on the bidirectional 23 interaction between individual microbiomes and celecoxib. Here we conducted in vitro 24 batch incubations of faecal microbiota to evaluate the short-term impact of celecoxib on 25 activity and composition of colon bacterial communities. Celecoxib-exposed microbiota 26 shifted metabolic activity and community composition, whereas total transcriptionally 27 active bacterial population was not significantly changed. Butyrate production decreased 28 by 50% in a donor-dependent manner, suggesting that celecoxib impacts in vitro 29 fermentation. Microbiota-derived acetate has been associated with inhibition of cancer 30 markers and our results suggest uptake of acetate for bacterial functions when celecoxib 31 was supplied, which potentially favoured bacterial competition for acetyl-CoA. We 32 further assessed whether colon microbiota modulates anti-inflammatory efficacy of 33 celecoxib using both a simplified inflammation model, and a novel in vitro simulation of 34 the enterohepatic metabolism. Celecoxib was responsible for only 5% of the variance in 35 bacterial community composition but celecoxib-exposed microbiota preserved barrier 36 function and decreased concentrations of IL-8 and CXCL16 in a donor-dependent manner 37 in our two cell models simulating inflammatory milieu in the gut. Our results suggest that 38 celecoxib-microbiome-host interactions may not only elicit adaptations in community 39 composition but also in microbiota functionality and may need to be considered for 40 guaranteeing efficient COX-2 inhibition. 41
IMPORTANCE: As inter-individual changes in the microbiome composition and 42
functionality may be a confounder on pharmacotherapy, we obtained mechanistic 43 understanding on how short-term celecoxib exposure impacts the functional activities of 44 colon communities. Celecoxib-exposed microbiota shifted metabolic activity without 45 impacting numbers of total active bacteria, but only community composition. Thus, 46 increased relative abundance of particular genera during celecoxib supplementation may 47 just indicate changes in maintenance energy. Focus on the influence of acetyl-CoA on 48 cancer cells and verifying whether changes in acetate:propionate:butyrate ratios rather 49 than in taxonomic diversity can be used as markers of decreased inflammation may be 50 the next frontiers for predicting successful NSAID therapy, and ultimately for developing 51 microbiome-based therapies. 52
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INTRODUCTION 55
Colorectal cancer (CRC) is the second most common cancer in the developed world (1), 56 and it is expected to increase by 60% in the next 20 years (2). Increased synthesis of 57 prostaglandins is a feature of chronic inflammation and has been proposed to promote 58 tumorigenesis in the colon (3). Prostaglandin E2 (PGE2) is a key mucosal inflammatory 59 mediator produced when membrane phospholipids are metabolized by cyclooxygenase 60 (COX) enzymes. Previous research showed that COX-2 expression was increased in CRC 61 (4), causing proliferation, enhanced angiogenesis and apoptosis suppression (5). In this 62 way, COX-2 inhibitors such as celecoxib are among the most promising chemopreventive 63 agents for CRC (6). Despite these benefits, their long-term use may shift cardiovascular 64 homeostasis, inhibiting biosynthesis of vascular COX-2 dependent prostacyclin (PGI2) 65 (7) and increasing cardiovascular events risk (8) . 66
Advances in omics techniques have provided insights on the role of the gut microbiome 67 in cancer development (9) . Currently, the driver-passenger model suggests that intestinal 68 "driver" bacteria contribute to initiate CRC by damaging epithelial DNA (10). This 69 microenvironment alteration impairs barrier function and favours opportunistic 70 "passenger" bacteria, placing selective pressure on the microbiome (10). 71
When colon-targeted drugs are orally administered, they encounter the gut microbiota 72 before reaching host tissues. Microbial drug metabolism may impact drug stability and 73 activity, influencing toxicity and inflammation on the host (11). Conversely, drugs may 74 also alter the gut microbiota, modulating community structure, and potentially resulting 75 in dysbiosis (12). Understanding microbiome-drug-host interactions will be crucial to 76 assess the potential impact on ADME and safety responses of intestinal targets. Although 77 the gut microbiome plays an enormous role in patient health, and in pharmacokinetic and 78 pharmacodynamic response (13), pharmaceutical companies have only recently started to 79 explore the microbiome as potential contributor to drug outcomes. Similarly, regulatory 80 agencies are not currently considering gut bacteria within the official evaluations before 81 approval of colon-targeted drugs. Besides the microbial modulation of drug 82 bioavailability and pharmacokinetics (11), low solubility and the small aqueous volume 83 in the colon may additionally hinder drug efficacy (14). As interest in developing novel 84 colon-targeted drug delivery systems for CRC has increased, insight into the presystemic 85 biotransformation by the gut microbiota is fundamental. In vitro studies have shown that 86 bacteria can metabolize celecoxib (15), potentially jeopardizing its anti-inflammatory 87 effects. Additionally, whether celecoxib presence can modulate the host-microbiome 88 crosstalk remains unresolved. Prior reports correlating gut microbiome changes with 89 celecoxib treatment relied on DNA amplicon sequencing (16). As the presence of dead 90 bacterial cells may obscure the interpretation from microbiome data, we analysed the 91 bacterial community composition based on cDNA, as a proxy for the metabolically active 92 community. 93
Colonic transit times (17-24 hrs) (17, 18) are longer compared to those of the small 94 intestine (3-4 hrs), and overall systemic absorption of poorly soluble drugs may be 95 improved with colon-delivery systems (17). Although celecoxib can be absorbed 96 throughout the GI tract, we simulated delivery in a proximal colon-targeted formulation 97 because of the environment vicinity between proximal colon and small intestine. Thus, 98 the aim of this research was to screen the short-term bidirectional interactions between 99 celecoxib and the microbiome of the in vitro proximal colon, and to elucidate the ultimate 100 impact of the microbiota on the anti-inflammatory efficacy of celecoxib. 101
102

RESULTS
103
Celecoxib impacts bacterial fermentative metabolism in a donor-dependent manner. 104 Short-chain Fatty Acids (SCFAs) were used to monitor functional activities of the colon 105 communities following exposure to celecoxib (CX) or its vehicle (PEG). Total SCFA 106 production from separate faecal microbiota incubations of 8 different individuals was 107 significantly lower for CX incubations compared to those with PEG (P < 0.05, Table 1) , 108 but pH remained stable throughout the experiment (Table 1) . While the 60:20:20 ratio of 109 the three major SCFA (acetate, propionate, and butyrate) was consistent across donors at 110 the initial time point ( Supplementary Table 1A ), a shift was evident at the end of the 111 incubation. Both relative and absolute concentrations of butyrate and propionate were 112 higher in samples treated with only PEG compared to those with CX. In fact, celecoxib 113 significantly lowered butyrate after 16 hours (P < 0.05, Table 1 ), except in donors 1, 4 114 and 8 ( Supplementary Table 1B ). In contrast, total active bacterial load remained 115 unchanged when celecoxib was supplemented (Table 1 , Supplementary Table 2 ). These 116 findings might indicate that bacteria either alter their metabolic activity when exposed to 117 CX or that changes in bacterial composition lead to shifts in fermentation profiles. 118
Bacterial abundance remains stable, but microbiome diversity and composition 119
shifted following celecoxib supplementation 120
Total DNA may also include that of dead bacterial cells, so we analysed community 121 composition based on cDNA, as a proxy for the metabolically active bacterial community 122
Quantitative RT-PCR revealed that total 16S rRNA gene copy numbers from 123 metabolically active bacteria were not significantly different between treatments, across 124 donors ( Supplementary Table 2 ). In contrast, community composition and structure were 125 influenced, as celecoxib was associated with reduced diversity at the end of the incubation 126 ( Figure 1 , Table 2A and 2B), with significant donor effect (PERMANOVA P < 0.001, 127 Figure 2 ). CX shifted alpha diversity and community composition metrics across donors 128 (Supplementary Table 3 , Figure 3 ). Although interindividual variability was significant, 129 that its relative abundance was associated with Subdoligranulum, a butyrate and lactate-144 producing genus, in a donor-dependent manner (P < 0.05, Supplementary Table 4 ). 145
Networks connecting bacterial load, metabolites and relative abundances were assembled 146 to monitor functional alterations associated with changes in genera abundances. Activity-147 based relative abundance of Bacteroides was positively associated with butyrate, 148 propionate and valerate levels and total 16S rRNA gene copy number in presence of PEG 149 ( Figure 5A , Supplementary Table 4 ). These results confirmed that Bacteroides was one 150 of the most abundant active genera, as first suggested in However, this genus tended to be positively associated with acetate production ( Figure  157 5B). Relative abundance of active Lachnoclostridium was significantly associated with 158 butyrate in the celecoxib treatment ( Figure 5B ). Here, Oscillospira, Allisonella, 159
Hungatella and Streptococcus were linked because they possibly participated in butyrate 160 production as well. Megamonas and Megasphaera were other genera with high relative 161
abundances positively associated with branched-chain SCFA and isovalerate. The 162 associations between the latter metabolites and Colinsella remained unchanged upon 163 celecoxib exposure, suggesting that this community function is either independent from 164 drug supplementation or directly associated with PEG addition ( Figure 5A and 5B). 165
Similarly, associations between Allisonella (butyrate consumer), Streptococcus (butyrate 166 producer) and butyrate were common for both treatments. Results from the network 167 analysis indicate that shifts in the community metabolic activity upon short-term 168 supplementation of celecoxib, potentially impacted butyrate production. 169
Inter-individual differences play a role in reduction of in vitro inflammation when 170
celecoxib is presented to the microbiome. 171
Understanding the microbial interactions with the host epithelium is essential to assess 172 whether the anti-inflammatory efficacy of celecoxib remains unaltered following 173 exposure to the simulated microbiome. We incorporated the immune component in a 174 simplified inflammation model using THP-1 (macrophage-like) cells. We further verified 175 the microbiome impact using a multicellular model simulating the enterohepatic 176 ecosystem, including enterocyte-like and goblet-like cell lines, plus THP-1 cells. This set-177 up enabled closer communication between cell lines, as would occur when macrophages 178 infiltrate the underlying intestinal mucosa. 179
Direct contact of macrophage-like cells with filter-sterilized supernatants from the CX-180 exposed microbiota resulted in a variable outcome in IL-8 and CXCL16 concentrations. 181
Compared with the PEG controls, a decrease in IL-8 and CXCL16 was only observed in 182 4 out of 8 individuals ( Figure 6A and 6B). 183
High IL-8 concentrations were found when non-bacterially exposed celecoxib was 184 applied in the enterohepatic model ( Figure 6C ). In contrast, the lowest concentration of 185 IL-8 and thus the most significant decrease in inflammatory response was found with the 186 celecoxib-exposed supernatant of donor 6 (P < 0.05, Table 3 ). Celecoxib that was not in 187 contact with bacteria promoted the highest decrease in transepithelial electrical resistance 188 (TEER) (P < 0.05, Table 3 ), in comparison with supernatants from celecoxib-exposed 189 bacteria. This outcome indicates less damage to epithelial barrier function and decreased 190 inflammatory response when gut microbiota is exposed to celecoxib. 191
192
DISCUSSION 193
As the lipophilic characteristics of celecoxib favour metabolic elimination (19), exploring 194 only the pathways for celecoxib distribution in the host is insufficient for assessing drug 195 bioavailability. In vitro models have been applied to simulate drug-bug associations in 196 the human gut (20, 21), but the impact of NSAIDs on the metabolic activities of the 197 microbiome has been overlooked. Previous studies reported the influence of different 198
NSAIDs on the gut microbiome (22), yet no changes in bacterial richness, microbiome 199 composition or beta diversity were found when celecoxib was supplied (16). These results 200 focused on screening community structure using DNA-based amplicon sequencing, 201 which may also include DNA of dead bacterial cells. As such approach may deliver a 202 partial overview, we used cDNA as an indicator of the metabolically active bacterial 203 population and we performed community composition analyses based on information 204 from transcribed RNA (23). In this way, we intended to highlight the main bacterial 205 genera whose metabolic activities were impacted by celecoxib in the RNA pool. Activity-206 based cell load was not significantly different, and the only alterations were on the 207 bacterial metabolic activities. Although composition, diversity and richness were not 208 significantly different as result of the treatment, differences in the most abundant genera 209 between PEG and celecoxib were observed. PERMANOVA analysis suggested that 210 donor was the main driver for dissimilarities in community structure. 211
The shifts in microbial metabolism observed in our study may indicate that celecoxib can 212 inhibit functional activities of bacterial groups, rather than of single genera, ultimately 213 impacting microbial fermentation (24). This was confirmed by the total active bacterial 214 load, which remained unchanged between treatments. Celecoxib users have been reported 215 to have enrichment of Enterobacteriaceae and Acidaminococcaceae (22). Here, we 216 validated that the relative abundance of transcriptionally active Escherichia-Shigella 217 (Enterobacteriaceae) was increased with celecoxib supplementation, whereas the relative 218 abundance of active Acidaminococcus (Acidaminococcaceae) was positively associated 219 with acetate in the same treatment. These results highlight the applicability of our in vitro 220 model used for this study. Coriobacteriaceae (Colinsella) has been proposed to participate 221 in xenobiotic metabolism by decreasing levels of serine and glycine (24), which can be 222 both fermented to acetate in the gut (25). We observed that the relative abundance of this 223 genus was positively associated with isovalerate levels when celecoxib was added. links with other genera in the celecoxib network. These potential cross-feeding 262 interactions (43, 44), may support its positive association with the total 16s rRNA gene 263 copy number. Acetate is a co-substrate for butyrate production (45), but butyrate 264 production may be reduced when NADH used for H 2 formation during glycolysis is not 265 available to convert acetoacetyl-CoA to butyryl-CoA (38). Acetate-producing 266
Lachnoclostridium and Oscillospira may have been involved in the shift from butyrate to 267 acetate production when celecoxib was supplied. This is because these genera possess 268 transporters involved in uptake of oligosaccharides and glycerol-P (43). Additionally, 269
Peptococcaceae uses the acetyl-CoA pathway in a reverse direction to oxidize butyrate 270 (46). Acetyl Co-A is consequently routed into acetate formation (45), which is 271 energetically advantageous for bacterial use (38). In fact, butyrate producers may shift 272 metabolic pathways towards acetate under stress conditions (47). As in our study, other 273 acetate producers such as Bacteroidetes and Prevotellaceae positively correlated to 274 butyrate-producing communities using the acetyl CoA pathway for butyrate production 275 (46), supporting the observed shift in butyrate towards acetate (48). 276
Although the role of SCFA on inflammation and CRC progression has been documented, 277 most of the studies lack natural commensal microbiota cross-talking with host cells (29, 278 31). As interindividual differences in microbiome play a crucial role on drug responses 279 (12), elucidating whether microbiome fermentation products synergistically act with 280
NSAIDs for impacting inflammation is paramount. Celecoxib was responsible for only 281 5% of the variance in bacterial community composition among the 8 donors, but the effect 282 of celecoxib-exposed bacteria on the proinflammatory IL-8 was sufficient to be detected 283 in a donor-dependent manner. Moreover, samples derived from 50% of the donors 284 showed increased CXCL-16, which is a marker of favourable prognosis in CRC (49). 285
This suggests that the interaction between celecoxib and microbiome to resolve 286 inflammation may be not solely related to community composition, and functionality 287 must be accounted for. While butyrate seemed to be reduced with short-term treatment, 288 Acetate:Propionate:Butyrate ratio and relative levels of acetate (of the total SCFA) may 289 be other functional bacterial metrics to be considered for assessing successful reduction 290 on inflammation when NSAIDs are administered. 291
As indicated in our study, gut microbiome activities and its interplay with the host can be 292 modulated through celecoxib. Our in vitro model retained interindividual variability, 293 allowing for mechanistic research on drug-microbiota-host interplay, fundamental for 294 developing individualised therapeutic strategies. Divergence in the molecular approaches 295 (i.e. next generation sequencing, qPCR) used for investigating CRC-associated 296 microbiome signatures contributes to the lack of consensus on the composition of 297 microbiota in CRC patients. Information on the role of SCFA in cancer signalling remains 298 inconclusive, and thus, future studies assessing the crosstalk of the microbiota and colon 299 cells in CRC are imperative. Certainly, individual microbiome may need to be considered 300 before supplementing celecoxib as a colon targeted drug for CRC. However, focusing on 301 functionality rather than taxonomic diversity may be the next frontier for developing 302 predictive markers of CRC-induced dysbiosis and NSAID efficacy. 303
MATERIALS AND METHODS 304
Faecal incubations simulating the proximal colon environment 305
Batch incubations of faecal samples were conducted using phosphate-buffered nutritional 306 medium (pH 5.9, 0. Once the incubation was completed, samples were collected, flash-frozen using liquid 324 nitrogen and preserved at -80 °C for further analysis. 325
Surveying community functionality and composition 326
Short-chain Fatty Acids (SCFAs) production. SCFA were used as benchmarks of 327 community activity. Extraction and analyses have been described by Truchado Sparse inverse covariance selection was employed to infer an association network within 390 treatments, using the package SpiecEasi (v0.1.2) (58) in R (v3.5.1). Neighbourhood 391 selection method (S-E(MB) was used to construct a network of bacterial genera 392 displaying core networks with either functional or phylogenetic similarities. The 393 calculated adjacency matrix was examined with the software Gephi 0.9.2 (59), using the 394 Fruchterman-Reingold algorithm for visualizing significant correlations (R ≥ 0.7). This 395 method computes a layout in which the length of the connections indicates the absolute 396 value of the correlation. The nodes representing genera whose relative bacterial 397 abundances have several significant correlations among them were placed closer to each 398 other in the network (50). 399
Bipartite networks highlighted functional associations among bacterial genera and 400 metabolites (52), using a pair-wise similarity matrix obtained from a Regularised 401 Canonical Correlation Analysis (60). Values of the similarity matrix were computed as 402 the correlation between relative abundances of bacterial genera and metabolic variables, 403 projected onto the space spanned by the first 3 components retained in the analysis 404 (r ≥ 0.75). Genera in the plot were close to correlated variables in the treatment where 405 they were more abundant (52). 406
Assessing the anti-inflammatory potential of bacteria-exposed celecoxib 407 diluted 1:5 with medium and added as controls of non-bacteria exposed celecoxib and 424 vehicle. This dilution step was performed to simulate low solubility and the small aqueous 425 volume in the colon (14). LPS (100 ng/mL) dissolved in RPMI 1640 was added to the 426 cells to simulate systemic inflammation, as in CRC. The control used in all measurements 427 was PMA-differentiated THP-1 macrophages exposed to the culture medium. subjected to the bacteria-exposed celecoxib from 3 of the volunteers screened (D1, D2 722 and D6). Two additional volunteers (D3 and D7) showed a trend for decreased IL-8, but 723 it was not significantly lower than the control treatment. (B) CXCL16 was significantly 724 lower in the simplified inflammation model subjected to the bacteria-exposed celecoxib 725 from only two volunteers (D2 and D6) and tended to be decreased in other two (D3 and 726 D4). (C) The two volunteers with the most extreme metabolic responses in butyrate 727 production were selected to be screened in a multicompartment cell model resembling the 728 enterohepatic system. Volunteer 6 (D6) had the most significant decrease in butyrate 729 levels and was considered "responder" to the CX treatment. Volunteer 8 (D8) did not 730 show any significant difference in butyrate between the control and the treatment after 16 731 h of incubation and it was considered as "non-responder". IL-8 concentration was 732 significantly lower in the model subjected to the supernatant of D6 containing bacteria-733 exposed celecoxib ("responder volunteer"). The opposite effect was observed in D8 734 ("non-responder volunteer"), suggesting that interindividual differences in the 735 functionality of the microbiome may play a role in the response to anti-inflammatory 736 drugs. 737 
